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Abstract: The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still
being investigated, but are known to involve oxidative stress, mitochondrial dysfunction, and the
dysregulation of autophagy. The objective of the current study was to examine the protective role
of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity. Sprague–Dawley
rats were divided into four groups at random. The doxorubicin-treated group received doxorubicin
(3 mg/kg every second day) intraperitoneally. The metformin-treated group received 250 mg/kg/day
metformin via gavage. The doxorubicin + metformin-treated group received both at the
above-mentioned doses. The control group received vehicle only. Following the two-week treatment,
the hearts were isolated, and cardiac functions were registered. Serum levels of lactate dehydrogenase
(LDH), creatine kinase iso-enzyme MB (CK-MB) enzyme, Troponin T, and cardiac malondialdehyde
(MDA) were also measured. Heart tissue samples were histopathologically examined by using
Masson’s trichrome staining and Western blot analysis was conducted for evaluating the expression
level of AMP-activated protein kinase (AMPK) and autophagy-associated proteins beclin-1, LC3B-II,
and p62, respectively. The results revealed that treatment with metformin conferred increased cardiac
protection against the development of cardiotoxicity manifested by a significant decrease in serum
Troponin T and cardiac MDA levels, and remarkable improvement in heart function in connection
with histopathological features. Furthermore, by focusing on the contribution of autophagic
proteins, it was found that metformin normalised autophagy, which may help cardiomyocytes
survive doxorubicin-induced toxicity. These results promote the use of metformin, which would be
a preferable drug for patients receiving doxorubicin.
Keywords: doxorubicin; metformin; AMPK; autophagy; cardiotoxicity; heart failure
1. Introduction
Doxorubicin (DOX) is a highly effective and widely-used non-selective class I anthracycline
antibiotic which is frequently incorporated in the treatment of acute leukemia, malignant lymphoma,
and several solid tumors [1,2]. However, the efficacy of DOX is hindered due to the cumulative
and irreversible cardiotoxicity, which is considered as the most prominent side effect, consequently
leading to the development of left ventricular dysfunction, dilated cardiomyopathy, and heart
failure years after the treatment has been stopped [3–5]. The molecular mechanisms underlying
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DOX-induced cardiotoxicity are multifactorial and are still unclear, but mitochondrial dysfunction,
oxidative stress, apoptosis, and dysregulation of autophagy are involved [6,7]. Furthermore, the heart is
very susceptible to DOX-induced lipid peroxidation and toxicity because of its high energy requirement
and mitochondrial density [8].
Autophagy is a highly conserved process which is aimed to maintain cell and tissue homeostasis,
and involves the elimination of damaged and long-lived organelles under both physiological and
pathological conditions [9], including energy and oxygen status, nutrient starvation, and modification
in metabolism [10]. Three types of autophagy can be described including microautophagy,
chaperone-mediated autophagy, and macroautophagy. The autophagy term hereafter refers to
macroautophagy in this study. The role of autophagy in cardiac tissue is apparently dual from the view
of survival or death; it depends on the type and the duration of the stress [11]. Several studies
have found that DOX treatment affects autophagy, however, it is still not clearly elucidated
how DOX alters this process. Previous studies on this matter have shown many controversial
results [7,12]. Recently reported studies have demonstrated that DOX induces autophagy; however,
it causes dysregulation in the autophagic flux and the autophagic process cannot be completed [13].
These findings are also supported by Hill and co-workers, showing that the administration of DOX
inhibits the lysosomal acidification, thus causing disruption in the autophagy flux [13]. In addition,
Tokarska et al. reported that DOX can cause dysregulation in most processes of myocardial energy
metabolism, such as the AMP-activated protein kinase (AMPK) signaling pathway [14]. AMPK is
a major sensor of cell energetic homeostasis. Low cellular energy levels and increased reactive oxygen
species (ROS) result in the phosphorylation and activation of AMPK, which is able to induce autophagic
processes [15–17].
Metformin (MET) is an orally used first-line anti-diabetic drug for the treatment of type 2 diabetes.
Several studies reported that application of MET decreases mortality and cardiovascular end-points of
type 2 diabetes and has protective effects in cardiac function [18,19].
Recently, several studies have found that MET activates AMPK, and through the AMPK signaling
pathway it induces cardiac autophagy and improves cardiac functions. Indeed, Kobashigawa and
colleagues demonstrated that cardioprotective effect of MET against DOX-induced toxicity is mediated
via upregulation of AMPK and its downstream target molecules [20]. However, high doses of MET
treatment induce the same alteration in the AMPK pathway, but its protective effect is lost. The authors
suggested that this could be due to the downregulation of platelet-derived growth factor receptor.
Furthermore, silencing of adiponectin receptors supressed AMPK activation and cell viability in MET-
and DOX-treated cells [21].
Nowadays, several extensive studies have investigated the role of autophagy in DOX-induced
cardiotoxicity, but we are one of the first research groups to investigate the effect of MET in the
autophagic process in DOX-treated animals under in vivo followed by ex vivo conditions.
Various studies have revealed that boosting or restoring autophagy could help the cardiomyocytes
to survive during DOX therapy. In the present study, we co-administered DOX and MET in order
to investigate the role of MET in the autophagic process and its cardioprotective properties in
DOX-induced cardiotoxicity. Thus, our investigation may offer further understanding of the role
of cardiac autophagy in DOX-treated animal subjects. In addition, our hypothesis was that MET could
activate AMPK, restore autophagy, and improve cardiac function, which may consequently mean
that DOX co-administered with MET help the cardiomyocytes to survive. This could be a promising
new strategy for patients suffering from cancer and receiving the DOX regimen. Moreover, it remains
a challenge to find an effective agent which might be combined with DOX that is able to reduce its
cardiotoxicity, whilst maintaining its efficacy and safety in tumor therapies.
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2. Results
2.1. DOX and MET Effects on Cardiac Function in Isolated Hearts
Figure 1 shows the cardiac function in hearts isolated from the animals 24 h after the last dose of
MET and/or DOX. Graph A demonstrates the aortic flow (AF), which was significantly lower (p < 0.05)
in the DOX group compared to the control group. This value was significantly higher in DOX+MET
group. Graph B expresses the coronary flow (CF), which showed no significant differences between
the control and the treated groups. Graph C displays no significant difference in aortic pressure (AOP)
among the four studied groups. We observed lower heart rate (HR) (not significant) in DOX-treated
group compared to the drug-free control group, while in the DOX+MET group, the values were almost
at the same level as the control group (Figure 1D). Furthermore, as per Figure 1E,F, a significant
decrease (p < 0.05) in cardiac output (CO) and stroke volume (SV) in DOX group compared to the
control group was detected. In the DOX+MET treated group, the CO was at a significantly higher
(p < 0.05) level, while SV was slightly increased (not significant).
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Figure 1. Effect of doxorubicin (DOX) and metformin (MET) on cardiac function (n = 17–19) of isolated
“working hearts” from rats after the 2-week treatment. Cardiac functions including aortic flow (A),
coronary flow (B), aortic pressure (C), heart rate (D), cardiac output (E), and stroke volume (F) were
recorded after 10 min in “working mode”. Results are provided as average magnitude of each cardiac
value within a group of animals± standard error of mean (SEM). The significance of differences among
groups were evaluated with one-way analysis of variance (ANOVA) followed by the Tukey comparison
test. p values of 0.05 or less were considered significant in each graph; * Significant difference the
control group vs. DOX group; ** Significant difference DOX group vs. DOX+MET group; # Significant
difference DOX group vs. MET group.
2.2. DOX and MET Effects on Serum Biomarkers
Figure 2 depicts that administration of 6 × 3 mg/kg of DOX alone resulted in a slight increase
in serum enzyme activities, such as lactate dehydrogenase (LDH) (Figure 2A) and creatine kinase
iso-enzyme MB (CK-MB) isotype (Figure 2B) compared to the control group, meanwhile in the
DOX+MET group, these enzymes remained at a lower level compared to the DOX-treated group.
In addition, we have found a significantly higher (p < 0.05) Troponin T level in DOX group compared
to the control (Figure 2C), while 250 mg/kg MET treatment resulted in a significantly lower level of
Troponin T compared to the DOX group, indicating that MET is able to reduce the detrimental effect
of DOX.
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2.3. DOX and MET Effects on Lipidperoxidation
One of the major contributors to DOX toxicity is oxidative stress. The results of the present study
showed that injection of 6 × 3 mg/kg DOX was associated with a considerably elevated level of
malondialdehyde (MDA) compared to the control group (Figure 3). While in the DOX+MET treated
group, the MDA level was significantly lower (p < 0.05) than in the DOX group.Molecules 2018, 23, x FOR PEER REVIEW    4 of 11 
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Figure 3. Effect of doxorubicin and metformin on the degree of lipid peroxidation (n = 10–12) after
the 2-week treatment. Malo dialdehyde level was measured from cardiac tissues by using a lipid
peroxidation assay. Results are provided as average magnitude of each value within a grou of animals
± SEM. The significance of differences a ong groups were evaluated with one-way alysis of varianc
(ANOVA) followed by the Tukey com arison t st. p values of 0.05 or less were c nsidered significant
in each graph; ** Significant difference DOX group vs. DOX+MET group; MDA: malo dialde yde.
2.4. DOX and MET Effects on Histopathological Features
DOX-induced cardiotoxicity was further assessed using trichrome staining. Representative
cross sections of each group and the graph displaying myofibrillar thickness are shown (Figure 4).
Cardiac tissues were stained with aniline blue for detection of fibrillar collagen and hence fibrosis.
Two weeks of treatment with DOX and/or MET did not show any visible differences in the amount
of collagen deposit in the treated groups. However, it is important to highlight that the myocytes
in DOX-treated groups were significantly thinner (p < 0.05) than in the control group. Furthermore,
the diameter of myocytes in the DOX+MET group was almost the same as the control group.
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2.5. DOX and MET Effects on AMPK and Autophagic Markers
Left ventricular tissue levels of AMPK were elevated in all three groups in comparison with
the control value (Figure 5A), but these changes were not at a significant level. Beclin-1 showed
a significantly increased (p < 0.05) expression level in the MET group compared to the control group,
while the DOX and DOX+MET groups did not show any changes in comparison with the control
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group (Figure 5B). LC3-II was significantly decreased (p < 0.05) in DOX group compared to the
control group, while in the DOX+MET group its expression was increased compared to the DOX
group (Figure 5C). For p62, a protein that recognizes toxic cellular waste, which is consequently
scavenged by a sequestration process, we observed the exact opposite change. A significantly increased
(p < 0.05) p62 level was detected in the DOX group compared to the control group, meanwhile,
for DOX co-administered with MET (DOX+MET), the expression of p62 was considerably lower
(Figure 5D), indicating that DOX treatment impaired autophagic protein clearance and it is restored
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Figure 5. The effect of doxorubicin and metformin on the expression level (n = 7–8) of pAMPK/AMPK
(A), Beclin-1 (B), LC3B-II (C), and p62 ( ) after 2- eek treat ents. The expression level of proteins
in left ventricular tissues as eval ate sing estern blot analysis. Results are provided as average
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test. p values of 0.05 or l s were considered significant in each graph; * Significant difference the
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difference DOX group vs. MET group; † Significant difference the control group vs. MET group.
3. Discussion
The major limitation of DOX treatment is the acute or chronic cardiac toxicity, which may result
in heart failure [22]. Acute toxicity could be reversible with adequate treatment; however, the life
expectancy of patients possessing DOX-induced heart failure is currently unclear. The underlying
mechanism appears to be multifactorial; however, enhanced oxidative stress is one of the major
contributors [23]. Indeed, cells fail to cope with an enhanced amount of reactive oxygen and
nitrogen species and enhanced oxidative stress leads to DNA and protein damage and mitochondrial
dysfunction [24]. In line with the literature, our results also show elevated oxidative stress evidenced
by an enhanced level of MDA in DOX-treated animals. Increased oxidative stress was accompanied by
impaired left ventricular functions including AF, CO, and SV in DOX-treated animals compared to the
control group. MET-only treatment did not significantly alter heart function or MDA levels. However,
our results revealed that MET co-treatment decreased oxidative stress and improved myocardial
function. In the present study, cardiac damage induced by DOX and serum levels of LDH, CK-MB,
and Troponin T were measured. Elevations in LDH and CK-MB levels represent their leakage from the
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damaged membranes of cardiomyocytes into circulation and were previously shown to be indicators
of cardiotoxicity [25,26]. The administration of 6× 3 mg/kg DOX alone resulted in a slight elevation in
serum enzyme levels in LDH and CK-MB, and serum Troponin T levels, which refer to the development
of cardiotoxicity of DOX. Troponin T molecules consisting of amino acid sequences that are found
only in cardiac tissue, making it highly specific for detecting cardiac damage. Meanwhile, in the
DOX+MET group, the levels of LDH and CK-MB remained at a lower level, and a significantly
lower level of Troponin T was also detected. Our results revealed that the daily administration of
MET significantly attenuated the rise of LDH, CK-MB, and Troponin T enzyme levels during the
DOX treatment, while the administration of MET alone did not show any significant changes in
serum enzyme levels. Confirming the cardioprotective effect of MET in DOX-induced cardiac toxicity,
histopathological analysis revealed that DOX treatment altered the size of myocytes, which was
restored in the presence of MET treatment. Earlier, Ashour and co-workers reported myofibrillar loss
and derangement with abnormal mitochondria in DOX-treated myocardium, which was partially
normalized when MET was administered to animals [27]. Furthermore, MET treatment decreased
the level of the apoptotic caspase 3 and enhanced the level of antiapoptotic Bcl-2 proteins, suggesting
that MET possesses antiapoptotic properties in this model [28]. Interestingly, sitagliptin, another
antihyperglicaemic agent, showed more potent cardioprotective effects.
Considering autophagy as a mechanism to restore energy status and to clear damaged
macromolecules [29], the expression of LC3B-II was studied, which is considered as a major marker of
macroautophagy. Upon DOX treatment, a significantly reduced level of LC3B-II protein expression
was found, suggesting that suppression of autophagy contributes to the detrimental effect of DOX.
Co-treatment with MET significantly enhanced the level of LC3B-II in comparison with DOX treatment,
suggesting that MET treatment normalized the autophagic process. Results with p62 protein strongly
support this hypothesis. One function of p62 is directing ubiquitinated protein to the autophagosome
for degradation. An enhanced level of p62 indicates impaired autophagic flux [30], and an enhanced
level of p62 in DOX-treated group suggests that autophagy is malfunctioning.
The alterations of these proteins were not significant between the control and DOX+MET treated
groups. Based on these two observations, we may assume that MET treatment normalized the
autophagic degradation. However, based on these results, we cannot conclude that MET itself
normalized the autophagic processes that leads to cardioprotection, or the cardioprotection induced
by MET leads to normalization of autophagic processes. Our results support the suggestion that
induction of autophagy before and during DOX treatment serves as a protective mechanisms against
cardiovascular complications [10].
In order to study the underlying mechanisms of autophagy induction, the phosphorylation level
of AMPK was studied in different groups. AMPK is an energy sensor of the cells, and MET induces
a mild inhibition of respiratory-chain complex I in the mitochondria, thereby influencing the AMP/ATP
ratio, leading to AMPK activation [31]. As expected, an enhanced level of p-AMPK in MET group was
detected, since AMPK is one of the target molecules of MET medication. The literature is more complex
regarding the effect of DOX treatment on the mechanism of AMPK activation/deactivation. The same
level of p-AMPK, like in samples originated from DOX-treated group, was observed, however, it was
not accompanied by enhanced autophagy. It is speculated that the enhanced phosphorylation of AMPK
is not a sufficient trigger to induce functioning autophagy if DOX is present, or even if autophagy is
being initiated, the whole process is not terminated. Moreover, an elevated level of p-AMPK in animals
treated with DOX and MET at the same time was measured, which was accompanied by a decreased
level of p62, indicating that autophagy is completed and damaged macromolecules are cleared.
Taken together, the results presented herein confirmed the cardioprotective ability of MET
in DOX-induced cardiac complications. The obtained results suggest that DOX treatment
impairs the autophagic processes, and damaged macromolecules cannot be degraded in the
cells, and co-administration of MET with DOX normalized the autophagic activity and confers
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cardioprotection. However, to draw a definitive cause–effect relationship between autophagy and
MET treatment, the autophagic flux needs to be directly examined.
4. Materials and Methods
4.1. Animals
The experiments were accomplished using adult female rats (Charles River Laboratories),
with a body weight range of 250–300 g. All animals were housed and treated according to the
“Principles of Laboratory Animal Care” formulated by the National Society for Medical Research
and the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy
of Sciences and published by the National Institutes of Health (NIH Publication no. 86-23, revised
in 1996). Maintenance and treatment of animals used in this study was additionally approved by
the Institutional Animal Care and Use Committee of the University of Debrecen, Debrecen, Hungary
(project ID: 3/2012/DE MAB, 03/2012–03/2017). The animals were housed in wire-bottomed cages
throughout the study and were maintained on 12:12-h light-dark cycle; and provided with laboratory
rodent chew pellets and water ad libitum.
4.2. Experimental Design and Treatment Protocol
Sprague–Dawley rats were randomly divided into four groups as follows I., control
group—animals received water per os, and saline intraperitoneally for a time period of 2 weeks;
II., MET group—animals received MET at a dose of 250 mg/kg every day orally via gavage [32],
and were injected with saline intraperitoneally; III., DOX group—animals received DOX at the dose of
3 mg/kg every second day intraperitoneally [27] (the cumulative dose was 18 mg/kg), and received
water orally; IV., DOX+MET group—animals received DOX intraperitoneally every second day and
MET each day orally at the above-mentioned dose. MET was dissolved in saline, and animals were
sacrificed 24 h after the last dose of MET and DOX. A schematic representation of the treatment
protocols and methods can be found in Supplementary Materials.
4.3. Isolated Working Heart Preparation and Cardiac Function Assessment
Following the 2-week treatment with vehicle, MET, and DOX respectively rats were anesthetized
with i.p. injection of pentobarbital (60 mg/kg), and heparin (1000 IU/kg) was intraperitoneally
administered as an anticoagulant. Blood samples were collected from the left jugular vein. Then,
thoracotomy was carried out under terminal anesthesia, followed by excision of the heart. The aorta
was cannulated and perfused in Langendorff “non-working” mode. Oxygenated Krebs–Henseleit
bicarbonate buffer (118.5 NaCl, 4.7 KCl, 2.5 CaCl2 × 2H2O, 25 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4,
and 10.0 glucose (in mM) was the perfusion medium. In the meantime, the pulmonary vein was
also cannulated, and the system was switched to the ”working” mode, as previously described by
Neely et al. [33], modified by Yamamoto et al. [34] and Tosaki and Hellegouarch [35]. After 10 min
of aerobic perfusion, the basic cardiac function was registered. Thus, aortic pressure (AOP) and
heart rate (HR) were registered using a computer acquisition system (ADInstruments, PowerLab,
Castle Hill, Australia). Coronary flow (CF) was obtained by timed collection of the coronary flow,
and aortic flow (AF) was measured by a calibrated flow-meter. Cardiac output (CO) was calculated as
the sum of AF and CF, and stroke volume (SV) was generated as the quotient of CO/HR.
4.4. Assessment of Serum Biomarkers
Blood samples were obtained from the left jugular vein, and the serum was separated for
measurement of LDH, CK-MB and Troponin T (TrT). For the in vitro quantitative determination
of the serum biomarkers electrochemiluminescence immunoassay “ECLIA” was used and measured
by Roche/Hitachi cobas immunoassay analyzers.
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4.5. Histopathological Examination
For histopathological examination, cardiac tissues were collected from all studied groups and
dissected and fixed in 4% formaldehyde solution. The heart samples were embedded in paraffin,
and five micron-thick sections were sliced. Standard histological methods (xylol) were used in order
to remove paraffin, and the samples were passed through a gradual alcohol series and hydrated.
Trichrome staining was used to demonstrate the general histological structure; it is a three-color staining
process, which differentially stains the nucleus, muscle tissue, and collagen. It was performed by
using Trichrome Stain Kit (Abcam, Cambridge, UK). The sections were studied under Olympus CX-31
microscope and photomicrographs were taken using Olympus DP74 camera (Olympus Corporation,
Tokyo, Japan) at 4× and 40× magnification. The remaining portion of the heart was stored at −80 ◦C
for lipid peroxidation assay and Western blot analysis.
4.6. Lipidperoxidation Assay
The level of MDA, in the heart tissue, was detected by using a lipid peroxidation
(malondialdehyde; MDA) assay kit (Sigma-Aldrich, St. Louis, MO, USA). Lipid peroxidation was
determined by the reaction of MDA with thiobarbituric acid (TBA) to form a colorimetric product,
proportional to the MDA present. The intensity of the color was measured spectrophotometrically at
532 nm.
4.7. Western Blot Analysis
The expression level of AMPK, p-AMPK, Beclin-1, LC3-II, and p62 proteins in left ventricular
tissue was evaluated using Western blot analysis. Approximately 300 mg of heart tissues were
homogenized by using a polytron homogenizer in isolating buffer (25 mM Tris-HCL, 25 mM NaCl,
1 mM orthovanadate, 10 mM NaF, 10 mM pyrophosphate, 10 mM okadaic acid, 0.5 mM EDTA,
1 mM PMSF, and 1× protease inhibitor cocktail) and centrifuged at 2000 rpm at 4 ◦C for 10 min.
The supernatant was transferred to a new tube and centrifuged at 10,000 rpm at 4 ◦C for 20 min,
and then the supernatant was used as cytosolic fraction. Protein concentration was measured by
a BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). A total of 75 µg of protein in each
sample was loaded and separated using electrophoresis on a polyacrylamide gel (TGX Stain-FreeTM
FastCastTM Acrylamide Kit, 12%, Bio-Rad, Hercules, CA, USA) and transferred onto a PVDF membrane.
Nonspecific binding sites were blocked with 7% skimmed milk in Tris-buffered saline solution with
0.5% Tween 20 for 1 hour at room temperature. Membranes were incubated overnight at 4 ◦C
with primary antibodies directed against AMPK, p-AMPK, Beclin-1, LC3-II, p62 (Cell Signaling
Technology, MA, USA). After washing the membranes, they were incubated with corresponding
horseradish-peroxidase-conjugated secondary antibodies for 1.5 h at room temperature and signal
intensities for each protein band was detected using Clarity Western ECL Substrate (Bio-Rad, California,
USA). The optical density of bands was measured using the ChemiDoc Touch Imaging System (Bio-Rad,
California USA). The level of the protein of interest was normalized against the total amount of protein
in each lane with the Bio-Rad Image Lab 5.2.1 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
4.8. Statistical Analysis
The data was analyzed by IBM SPSS Statistics 22.0 statistical software (IBM Corporation, New York,
NY, USA) The data are expressed as mean± standard error of the mean (mean± 1 SE). The significance of
differences among groups was evaluated with one-way analysis of variance (ANOVA) followed by the
Tukey comparison test. For the histopathological examination Mann–Whitney test was used to evaluate
the data. p values of 0.05 or less were considered to be significant.
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5. Limitation of the Study
One limitation of this study was that the cardiac function and serum biomarkers were measured
and examined only 24 h after the administration of the last dose of DOX. Therefore, we were unable
to determine the long-term effects of the co-administration of these two drugs. Another limitation of
the study is that DOX was intraperitoneally administered, whereas the protocols for patients involve
intravenous administration.
Supplementary Materials: Supplementary Materials can be found online.
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